Chugai Pharmaceutical Management
Management criteria checks 1/4
Chugai Pharmaceutical's CEO is Osamu Okuda, appointed in Mar 2020, has a tenure of 4.75 years. total yearly compensation is ¥375.00M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth ¥1.11B. The average tenure of the management team and the board of directors is 3.9 years and 1.8 years respectively.
Key information
Osamu Okuda
Chief executive officer
JP¥375.0m
Total compensation
| CEO salary percentage | 31.7% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.9yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Share Price Could Signal Some Risk
Dec 23
Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Dec 05Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?
Oct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Sep 24Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 30Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00
Jul 27Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Jul 15Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00
Jun 19Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't
Jun 17Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year
May 04We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings
May 01Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Apr 26Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected
Mar 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | JP¥387b |
| Jun 30 2024 | n/a | n/a | JP¥355b |
| Mar 31 2024 | n/a | n/a | JP¥326b |
| Dec 31 2023 | JP¥375m | JP¥119m | JP¥325b |
| Sep 30 2023 | n/a | n/a | JP¥337b |
| Jun 30 2023 | n/a | n/a | JP¥327b |
| Mar 31 2023 | n/a | n/a | JP¥316b |
| Dec 31 2022 | JP¥298m | JP¥108m | JP¥374b |
| Sep 30 2022 | n/a | n/a | JP¥371b |
| Jun 30 2022 | n/a | n/a | JP¥389b |
| Mar 31 2022 | n/a | n/a | JP¥387b |
| Dec 31 2021 | JP¥252m | JP¥85m | JP¥303b |
| Sep 30 2021 | n/a | n/a | JP¥256b |
| Jun 30 2021 | n/a | n/a | JP¥231b |
| Mar 31 2021 | n/a | n/a | JP¥211b |
| Dec 31 2020 | JP¥84m | JP¥40m | JP¥215b |
Compensation vs Market: Osamu's total compensation ($USD2.38M) is above average for companies of similar size in the JP market ($USD1.36M).
Compensation vs Earnings: Osamu's compensation has increased by more than 20% in the past year.
CEO
Osamu Okuda (61 yo)
4.8yrs
Tenure
JP¥375,000,000
Compensation
Dr. Osamu Okuda serves as Representative Director and President at Chugai Pharmaceutical Co., Ltd. since March 30, 2020 and its Chief Executive Officer since March 23, 2021. He serves as Chairman at Chugai...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | JP¥375.00m | 0.0096% ¥ 1.1b | |
| Executive VP | less than a year | no data | 0.00012% ¥ 13.8m | |
| Executive of Investor Relations Group & Corporate Communications Department | no data | no data | no data | |
| VP and Head of Quality | less than a year | no data | no data | |
| Head of Marketing & Sales Division | no data | no data | no data | |
| Executive Vice President | less than a year | no data | no data | |
| Executive Vice President | 3.9yrs | no data | no data | |
| Senior VP & Full-time Audit Supervisory Board Member | 9.9yrs | no data | 0.0030% ¥ 343.2m | |
| Executive VP & Head of PHC Solution Unit | 4.9yrs | no data | no data | |
| Executive Vice President | no data | no data | no data | |
| Head of PHC Solution Department | no data | no data | no data | |
| VP & Head of Research Division | no data | no data | no data |
3.9yrs
Average Tenure
61yo
Average Age
Experienced Management: 4519's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | JP¥375.00m | 0.0096% ¥ 1.1b | |
| Executive VP | less than a year | no data | 0.00012% ¥ 13.8m | |
| Senior VP & Full-time Audit Supervisory Board Member | 3.8yrs | no data | 0.0030% ¥ 343.2m | |
| Executive VP | less than a year | no data | 0.00018% ¥ 20.7m | |
| Member of the International Advisory Council | no data | no data | no data | |
| Honorary Chairman & Senior Advisor | 4.8yrs | JP¥211.00m | no data | |
| Member of the International Advisory Council | no data | no data | no data | |
| Member of the International Advisory Council | no data | no data | no data | |
| Member of the International Advisory Council | no data | no data | no data | |
| Chairman of the International Advisory Council | no data | no data | no data | |
| Outside Independent Director | 1.8yrs | no data | no data | |
| Non-Executive Director | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
75yo
Average Age
Experienced Board: 4519's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 03:17 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |